An internal standard for the quantification of irbesartan
Related Products
Unlabeled Version(s)
11952Irbesartan
Technical Support & Resources

Visit our FAQ

Contact Us

Toll Free Phone (USA and Canada Only): (888) 526-5351
Direct Phone: (734) 975-3888

Request Technical Support

Technical Support Request

To streamline the process attach the appropriate questionnaire to your inquiry.

Download IHC QuestionnaireDownload WB Questionnaire

View Our Privacy Statement for details on how we use and protect your data. In addition, this site is protected by hCaptcha and its Privacy Policy and Terms of Service apply.

Irbesartan-d4

Item No. 25509

Technical Information
Formal Name
3-((2'-(2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl-2,3,5,6-d4)methyl)-2-butyl-1,3-diazaspiro[4.4]non-1-en-4-one
CAS Number
1216883-23-6
Molecular Formula
C25H24D4N6O
Formula Weight
Purity
≥99% deuterated forms (d1-d4)
Formulation
A solid
Methanol: Heated
SMILES
CCCCC1=NC2(CCCC2)C(N1CC3=C([2H])C([2H])=C(C4=C(C5=NNN=N5)C=CC=C4)C([2H])=C3[2H])=O
InChi Code
InChI=1S/C25H28N6O/c1-2-3-10-22-26-25(15-6-7-16-25)24(32)31(22)17-18-11-13-19(14-12-18)20-8-4-5-9-21(20)23-27-29-30-28-23/h4-5,8-9,11-14H,2-3,6-7,10,15-17H2,1H3,(H,27,28,29,30)/i11D,12D,13D,14D
InChi Key
YOSHYTLCDANDAN-WQKXEYJYSA-N
Shipping & Storage Information
Storage
-20°C
Shipping
Room temperature in continental US; may vary elsewhere
Recommended Products

Certificates of Analysis & Batch Specific Data

Provide batch numbers separated by commas to download or request available product inserts, QC sheets, certificates of analysis, data packs, and GC-MS data.

    Add

    Add

    Cayman Chemical
    Explore Obesity & Metabolic Disease Resources

    Discover high-quality research tools to investigate GLP-1 mechanisms and next-generation metabolic targets.

    OBESITY RESEARCH SOLUTIONS
    Product Description

    Irbesartan-d4 is intended for use as an internal standard for the quantification of irbesartan (Item No. 11952) by GC- or LC-MS. Irbesartan is an antagonist of the angiotensin II type 1 (AT1) receptor (Ki = 1.3 nM).1 It is an insurmountable antagonist of AT1, as its antagonism cannot be overcome by increasing concentrations of angiotensin II.2 Irbesartan (3, 10, and 30 mg/kg) reduces blood pressure in stroke-prone spontaneously hypertensive rats and increases survival of SPSH rats fed a high-salt low-protein diet.3 It also reduces plaque formation, collagen content, as well as the increased expression of the AT1 receptor, PDGF-b, MCP-1, and VCAM-1 in a model of diabetes-induced atherosclerosis using apolipoprotein E (ApoE) knockout mice with diabetes induced by streptozotocin (STZ; Item No. 13104).4 Formulations containing irbesartan have been used, alone and in combination with diuretics, in the treatment of hypertension.

    WARNING This product is not for human or veterinary use.

    References & Product Citations
    Product Description References

    1. Burnier, M. Angiotensin II type 1 receptor blockers. Circulation 103(6), 904-912 (2001).

    2. Gradman, A.H. AT1-receptor blockers: Differences that matter. J. Hum. Hypertens. 16, S9-S16 (2002).

    3. Shimamura, T., Masui, M., Torii, M., et alHypotensive and prophylactic effects of angiotensin II subtype 1 receptor antagonist, irbesartan, in stroke-prone spontaneously hypertensive rats. Clin. Exp. Hypertens. 26(1), 27-42 (2004).

    4. Candido, R., Allen, T.J., Lassila, M., et alIrbesartan but not amlodipine suppresses diabetes-associated atherosclerosis. Circulation 109(12), 1536-1542 (2004).